Considering the immunosuppressive role of A2AR on T and NK cells, rational combination strategies targeting the ADO pathway with checkpoint inhibitors and adoptive cell therapies (ACT) have the potential to synergistically enhance anti-tumour immune cell function. The gene discussed is ADORA2A; the disease is neoplasm.